- Trials with a EudraCT protocol (76)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
76 result(s) found for: Umbilical Cord Blood.
Displaying page 3 of 4.
| EudraCT Number: 2010-024253-36 | Sponsor Protocol Number: 10MI29 | Start Date*: 2012-08-03 | |||||||||||
| Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | |||||||||||||
| Full Title: Phase I/II, historical controlled, open-label, non-randomised, single-centre trial to assess the safety and efficacy of EF1αS-ADA lentiviral vector mediated gene modification of autologus CD34+ cel... | |||||||||||||
| Medical condition: Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). Children with SCID lack virtually all immune protect... | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-000770-29 | Sponsor Protocol Number: Ireland-RctV8 | Start Date*: 2018-06-18 | ||||||||||||||||
| Sponsor Name:The Rotunda Hospital | ||||||||||||||||||
| Full Title: Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diab... | ||||||||||||||||||
| Medical condition: Pregestational type I or type II diabetes | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-003913-36 | Sponsor Protocol Number: REFSAL | Start Date*: Information not available in EudraCT |
| Sponsor Name:Warszawski Uniwersytet Medyczny | ||
| Full Title: Evaluation of frequency occurrence persistent pulmonary hypertension of newborns in group of newborns born between 32 and 42 weeks of pregnancy treated by salbutamol | ||
| Medical condition: Persistent pulmonary hypertension of newborns in group of newborns born between 32 and 42 weeks of pregnancy | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
| Trial protocol: PL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002942-30 | Sponsor Protocol Number: 01012015 | Start Date*: 2015-12-10 | ||||||||||||||||
| Sponsor Name:Regional Hospital of Randers | ||||||||||||||||||
| Full Title: CONDISOX: Continued versus discontinued oxytocin stimulation of labour in a double-blind randomised controlled trial | ||||||||||||||||||
| Medical condition: Syntocinon is used for labour induction to stimulate contractions. The current recommendation is to stimulate until delivery. We hypothesize that discontinuation of Syntocinon when the active phase... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: DK (Completed) NL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-004478-80 | Sponsor Protocol Number: Issue1 | Start Date*: 2014-01-08 | |||||||||||||||||||||
| Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||
| Full Title: XENON AND COOLING THERAPY IN BABIES AT HIGH RISK OF BRAIN INJURY FOLLOWING POOR CONDITION AT BIRTH: A RANDOMISED OUTCOME STUDY (COOLXENON3 STUDY) | |||||||||||||||||||||||
| Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-001577-70 | Sponsor Protocol Number: RESCAT | Start Date*: 2020-12-28 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
| Full Title: Allogeneic Mesenchymal Stromal Cell (MSC) Therapy for SARS-CoV-2 Pneumonia: A Prospective Randomized Multicentre Phase I/IIa Open Label Study | |||||||||||||
| Medical condition: SARS-CoV-2 pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-018450-12 | Sponsor Protocol Number: 706079098 | Start Date*: 2010-08-18 | |||||||||||
| Sponsor Name:Agneta Blanck Olerup | |||||||||||||
| Full Title: Optimising pain control after caesarean section - an evaluation if oxycodone can replace morphine and low potency opioids postoperatively. | |||||||||||||
| Medical condition: Pain management after elective cesarean section. | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001400-29 | Sponsor Protocol Number: P150302J | Start Date*: 2018-03-16 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord - MSC SLE | |||||||||||||
| Medical condition: Treatment of Systemic Lupus Erythematosus refractory to standard treatments. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017026-39 | Sponsor Protocol Number: UCBT-002 | Start Date*: 2009-12-28 | |||||||||||
| Sponsor Name:Aldagen, Inc | |||||||||||||
| Full Title: A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISM | |||||||||||||
| Medical condition: Inborn errors of metabolism | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011921-15 | Sponsor Protocol Number: UCBT-002 | Start Date*: 2009-06-22 | |||||||||||
| Sponsor Name:Aldagen, Inc | |||||||||||||
| Full Title: A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISM | |||||||||||||
| Medical condition: Inborn errors of metabolism | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Not Authorised) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-014260-19 | Sponsor Protocol Number: CH/2009/3187 | Start Date*: 2010-01-29 | |||||||||||||||||||||||||||||||
| Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||||||||||||
| Full Title: A feasibility study of adding xenon to cooling therapy in babies at high risk of brain injury following poor condition at birth | |||||||||||||||||||||||||||||||||
| Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-003686-17 | Sponsor Protocol Number: WiNK | Start Date*: 2020-07-03 | |||||||||||
| Sponsor Name:Glycostem Therapeutics BV | |||||||||||||
| Full Title: A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute my... | |||||||||||||
| Medical condition: acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) FR (Completed) NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020797-41 | Sponsor Protocol Number: NEMO1-08NR26 | Start Date*: 2010-11-16 | |||||||||||
| Sponsor Name:Only for Children Pharmaceuticals | |||||||||||||
| Full Title: NEMO-1: An open label exploratory dose finding and pharmacokinetic clinical trial of bumetanide for the treatment of NEonatal seizure using Medication Off-patent. | |||||||||||||
| Medical condition: Neonatal Seizures in Hypoxic Ischemic Encephalopathy | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000620-17 | Sponsor Protocol Number: PPL17 | Start Date*: 2019-05-08 | |||||||||||
| Sponsor Name:Dilafor AB | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study (section A) with a conditional dose finding follow up (Section B) to Evaluate the Efficacy on Cervical ripening... | |||||||||||||
| Medical condition: Induction of labor in pregnant women with unripe cervix | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004726-34 | Sponsor Protocol Number: SHP620-302 | Start Date*: 2017-09-01 | |||||||||||
| Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
| Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru... | |||||||||||||
| Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000062-14 | Sponsor Protocol Number: MN42988 | Start Date*: 2021-10-08 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY | ||||||||||||||||||
| Medical condition: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications] | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: In utero, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-001929-27 | Sponsor Protocol Number: NK4AML | Start Date*: 2020-05-20 |
| Sponsor Name:Radboud University Medical Centre | ||
| Full Title: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’ | ||
| Medical condition: AML patients who do not have rapid progressive disease with or without disease controlling medication and who are not eligible for allogeneic SCT. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004482-14 | Sponsor Protocol Number: P160917 | Start Date*: 2019-08-14 |
| Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | ||
| Full Title: Tocolysis in the management of preterm premature rupture of membranes before 34 weeks of gestation: a double-blinded randomized controlled trial | ||
| Medical condition: Pregnant women with PPROM at 22 to 33 weeks gestation | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004883-23 | Sponsor Protocol Number: APHP191116 | Start Date*: 2020-10-06 | |||||||||||
| Sponsor Name:APHP | |||||||||||||
| Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adu... | |||||||||||||
| Medical condition: Adult patients (n=10) requiring an allogeneic HSCT for the treatment of AML with an unfavorable prognosis according to international criteria in first complete remission or second complete remissio... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005397-34 | Sponsor Protocol Number: Issue1 | Start Date*: 2012-02-24 | |||||||||||||||||||||
| Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||
| Full Title: Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study) | |||||||||||||||||||||||
| Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.